HISTOGEN INC has a total of 52 patent applications. Its first patent ever was published in 2009. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are QUARRYMEN CORP, BONE THERAPEUTICS SA and CHANCELLOR MICHAEL B.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Canada | 6 | |
#4 | EPO (European Patent Office) | 6 | |
#5 | Australia | 5 | |
#6 | China | 4 | |
#7 | Republic of Korea | 4 | |
#8 | Brazil | 3 | |
#9 | Singapore | 2 | |
#10 | African Regional Industrial Property Organization | 1 | |
#11 | Hungary | 1 | |
#12 | Japan | 1 | |
#13 | Mexico | 1 | |
#14 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Organic fine chemistry | |
#5 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Object sterilising | |
#5 | Specific use of cosmetics | |
#6 | Peptides | |
#7 | Microbiology | |
#8 | Heterocyclic compounds | |
#9 | Foods |
# | Name | Total Patents |
---|---|---|
#1 | Naughton Gail K | 40 |
#2 | Nickey Kyle | 21 |
#3 | Baumgartner Mark | 21 |
#4 | Ziegler Frank | 14 |
#5 | Pinney Emmett | 13 |
#6 | Zeigler Frank | 11 |
#7 | Naughton Gail | 5 |
#8 | Frank Ziegler | 4 |
#9 | Zimber Michael | 4 |
#10 | Mark Baumgartner | 4 |
Publication | Filing date | Title |
---|---|---|
WO2020223543A1 | Conditioned medium and methods of use thereof | |
CA3107592A1 | Conditioned medium and extracellular matrix compositions and uses thereof | |
CA3105352A1 | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases | |
AU2019214938A1 | Extracellular vesicles derived from cells cultured under hypoxic conditions and uses thereof | |
WO2019140267A1 | Nutraceutical products from cell conditioned medium from cells cultured under hypoxic conditions | |
CA2983832A1 | Extracellular matrix compositions for the treatment of cancer or immuno logical diseases | |
AU2010271212A1 | Conditioned medium and extracellular matrix compositions from cells cultured under hypoxic conditions | |
US2010166824A1 | Extracellular matrix compositions | |
CA2714387A1 | Extracellular matrix compositions | |
CN102497871A | Extracellular matrix compositions for the treatment of cancer |